1,2,3,4-Tetrahydro-5H-[1,3]benzodioxolo[5',6':5,6]pyrano[3,4-c]pyridin-5-one hydrochloride | 86370-95-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 1,2,3,4-Tetrahydro-5H-[1,3]benzodioxolo[5',6':5,6]pyrano[3,4-c]pyridin-5-one hydrochloride
• 英文别名: 9,13,15-trioxa-5-azatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),2(7),10,12(16)-tetraen-8-one;hydrochloride
• CAS: 86370-95-8
• 化学式: C₁₃H₁₁NO₄*ClH
• 分子量: 281.696
• InChiKey: CBRHJGSMQJPJHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  56.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,2,3,4-Tetrahydro-5H-[1,3]benzodioxolo[5',6':5,6]pyrano[3,4-c]pyridin-5-one hydrochloride 、 一氯丙酮 生成 1,2,3,4-tetrahydro-3-(2-oxopropyl)-5H-[1,3]benzodioxolo[5',6':5,6]pyrano[3,4-c]pyridin-5-one
  参考文献：
  名称：

  CONNOR, D. T.;SCHWENDER, C. F.;SORENSON, R. J.;UNANGST, P. C.

  摘要：

  DOI：
• 作为产物：
  描述：

  芝麻酚 、 4-氧代哌啶-3-羰酸甲酯 盐酸盐 在 硫酸 作用下， 以47%的产率得到1,2,3,4-Tetrahydro-5H-[1,3]benzodioxolo[5',6':5,6]pyrano[3,4-c]pyridin-5-one hydrochloride
  参考文献：
  名称：

  1,2,3,4-四氢-5 H- [1]苯并吡喃并[3,4- c ]吡啶-5-酮的合成。I.3-未取代的化合物

  摘要：

  通过3-碳乙氧基-1-甲基-4-哌啶酮与各种酚的Pechmann缩合反应合成1,2,3,4-四氢-5 H- [1]苯并吡喃并[3,4- c ]吡啶-5-描述。讨论了该方法的局限性。母环系统的合成图3a经由还原的1,2,3,4-四氢-3-（苯基甲基）-8 - [（1-苯基-1- ħ -四唑-5-基）氧基] -5- ħ - [还描述了1]苯并吡喃并[3,4- c ]吡啶-5-一（5）。

  DOI：

  10.1002/jhet.5570210563

文献信息

• 3-[2-(Azabicyclo)
  申请人：Warner-Lambert Company

  公开号：US04404138A1

  公开（公告）日：1983-09-13

  Anticholinergic 3-[2-(azabicyclo)ethyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin -5-ones useful for treating bronchospastic diseases in mammals are disclosed. Also disclosed are methods for preparing said compounds, pharmaceutical compositions containing them and methods for using said pharmaceutical compositions.

  抗胆碱药物3-[2-(氮杂双环)乙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]吡啶-5-酮，用于治疗哺乳动物的支气管痉挛性疾病。还公开了制备这些化合物的方法，含有它们的药物组合物以及使用这些药物组合物的方法。
• 3-[2-(Mono-and
  申请人：Warner Lambert Company

  公开号：US04382939A1

  公开（公告）日：1983-05-10

  Anticholinergic 3-[2-(mono- and dialkylamino)-propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]-pyridin- 5-ones useful for treating bronchospastic diseases in mammals are disclosed. Also disclosed are methods for preparing said compounds, pharmaceutical compositions containing them and methods for using said pharmaceutical compositions. A method for preparing the intermediate which is required to prepare the unsubstituted benzopyrano-[3,4-c]pyridin-5-ones of the invention is also disclosed.

  本发明揭示了用于治疗哺乳动物的支气管痉挛性疾病的抗胆碱能3-[2-(单烷基和双烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]-吡啶-5-酮。还揭示了制备所述化合物的方法，包含它们的制药组合物和使用所述制药组合物的方法。还揭示了制备本发明所需的未取代苯并吡喃-[3,4-c]吡啶-5-酮中间体的方法。
• 3-(2-Mono-and dialkylamino)propyl(-1,2,3,4-tetrahydro-5H-(1) benzopyrano(3,4-c)pyridin-5-ones and derivatives thereof, a process for their production, and pharmaceutical compositions containing such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0087280A2

  公开（公告）日：1983-08-31

  Antichofinergic 3-[2-(mono- and dialkylamino)-propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-c]-pyridin-5-ones, useful for treating bronchospastic diseases in mammals, are disclosed. Also disclosed are processes for preparing the compounds, and pharmaceutical compositions containing them. The novel compounds have the following formula: where X is a lower alkyl radial, Y is hydrogen or a lower alkyl, and R', R2 and R3 are, separately, hydrogen atoms or substituents. A process for preparing the intermediate which is required to prepare the unsubstituted benzopyrano-[3,4-c]pyridin-5- ones of the present invention is also disclosed

  本发明公开了可用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能 3-[2-(单烷基和二烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃并[3,4-c]吡啶-5-酮。 还公开了制备这些化合物的工艺和含有这些化合物的药物组合物。 这些新型化合物具有下式：其中 X 是低级烷基径向，Y 是氢或低级烷基，R'、R2 和 R3 分别是氢原子或取代基。 还公开了制备本发明未取代苯并吡喃并[3,4-c]吡啶-5-酮所需的中间体的工艺
• CONNOR, D. T.;SCHWENDER, C. F.;SORENSON, R. J.;UNANGST, P. C.
  作者：CONNOR, D. T.、SCHWENDER, C. F.、SORENSON, R. J.、UNANGST, P. C.

  DOI：——

  日期：——
• CONNOR, D. T.;UNANGST, P. C.;SCHWENDER, CH. F.;SORRENSON, R. J.;CARETHERS+, J. HETEROCYCL. CHEM., 1984, 21, N 5, 1557-1559
  作者：CONNOR, D. T.、UNANGST, P. C.、SCHWENDER, CH. F.、SORRENSON, R. J.、CARETHERS+

  DOI：——

  日期：——